iBio licenses first-in-class anti-Activin E antibody from AstralBio for up to $28M in milestones

iBio, Inc.

Upfront $750K credit applied toward option fee; total milestone payments up to $28M, payable in cash or stock.
Antibody demonstrated fat-selective weight loss and synergy with GLP-1 in obese rodent model.
iBio also amended AstralBio collaboration to add a fifth cardiometabolic target using its AI platform.
AstralBio eligible for low to mid-single-digit sublicense fees on any sublicense proceeds.
iBio solely responsible for all development, manufacturing, and commercialization worldwide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.